双歧杆菌四联活菌联合谷维素治疗肠易激综合征的临床观察

目的探讨双歧杆菌四联活菌联合谷维素治疗肠易激综合征的临床疗效。方法将68例肠易激综合征患者随机分为观察组和对照组,每组34例。两组患者均予以口服匹维溴胺50 mg/次,3次/d。对照组加用谷维素30 mg,3次/d口服。观察组在对照组治疗的基础上加用双歧杆菌四联活菌片1.5 g,3次/d口服。两组患者疗程均为12周。结果观察组总有效率94.12%,对照组总有效率76.47%。两组患者临床疗效比较,差异有统计学意义(P<0.05)。两组患者治疗后临床消化道症状评分与治疗前比较均明显改善,治疗前后比较差异有统计学意义(P<0.05或P<0.01);治疗后,观察组临床消化道症状评分显著优于对照组(P<0.05)。两组患者治疗后汉密尔顿抑郁量表和焦虑量表评分与治疗前比较均明显改善,治疗前后比较差异有统计学意义(P<0.01);治疗后,观察组汉密尔顿抑郁量表和焦虑量表评分显著优于对照组,两组比较差异有统计学意义(P<0.05)。结论双歧杆菌四联活菌联合谷维素治疗肠易激综合征疗效肯定,且在联合治疗过程中,未见明显的毒副作用,各项安全性指标均正常,耐受性及安全性良好。

Clinical observation of tetralogy of viable bifidobacterium combined with oryzanol treatment for irritable bowel syndrome

Objective To investigate the clinical efficacy of tetralogy of viable bifidobacterium combined with oryzanol on irritable bowel syndrome.Methods 68 patients with irritable bowel syndrome were divided into observation group and control group,34 cases each group.Both groups were given 50 mg pinaverium bromide orally,three times a day.Control group was given 30 mg oryzanol orally in addition,three times a day.Observation group was given 1.5 g tetralogy of viable bifidobacterium tablets orally,three times a day.Both groups were treated for 12 weeks.Results The total effective rate of observation group and control group were 94.12% and 76.47% respectively,there was significant difference in clinical efficacy between the two groups(P<0.05).After treatment the clinical gastrointestinal symptom score of both groups were much better(P<0.05 or P<0.01).And the clinical gastrointestinal symptom score of the observation group was obviously better than that of control group(P<0.05).The scores of HAMD and HAMA after treatment of both groups were obviously improved(P<0.01).The scores of HAMD and HAMA of observation group were much better than those of control group(P<0.05).Conclusion The clinical efficacy of tetralogy of viable bifidobacterium combined with oryzanol in treating irritable bowel syndrome are confirmed,and there are no obvious toxic and side effects.All safety indicators are normal with good tolerance and safety.